Market Scope

Rising investments in poultry farms due to the increasing gravitation towards protein by consumers can boost the global avian influenza vaccine market demand. Researchers at Kansas University had collaborated with Icahn School of Medicine for development of a vaccine against strains of bird flu. Development of live vaccines for enhancing the immunity of birds against germs and bacteria can bode well for the market.

The global avian influenza vaccine market size is predicted to reach USD 735.22 million by 2025. It can garner revenues at 7.25% CAGR over the forecast period. Large cases of avian diseases are one of the biggest drivers of the market. The sudden outbreak of avian flu in 2008 has culminated in culling of birds on a large scale. In order to avoid a repeat of the incident, vaccine manufacturers are investing in research and development to create possible vaccines for various strains of the H5N1 virus. This is exemplified by the license conferred to Sanofi Pasteur by the U.S. FDA for the H5N1 vaccine.

Segmentation

The global avian influenza vaccine market has been segmented by strain and application.

The market, based on strain, has been segmented into H5, H7, and H9.

Based on application, the avian influenza vaccine market has been segmented into goose duck, chicken, and turkey.

Regional Analysis

The global avian influenza vaccine market, based on region, has been divided into the APAC Middle East, Europe, Americas, and Africa.

The APAC Middle East is likely to dominate the global avian influenza vaccine market. This can be attributed to the increasing production of poultry and the subsequent rise in avian influenza outbreaks in the region. According to a recent report from the Foreign Agricultural Service/USDA, China had registered 13,800 thousand metric tons of chicken meat production in 2019. Furthermore, various government initiatives for rapid and effective response for zoonotic diseases can augur favorably for the market.

Europe is estimated to be the second-largest region during the review period. The growing dependence on poultry for protein and presence of various biotechnology firms for production of vaccines can influence the regional market growth. According to the European Commission, the European Union (EU) produced 15.2 million tons of poultry meat in 2018. Rise of veterinary clinics and production of meat can both evoke massive demand in the global avian influenza vaccine market.

The Americas is estimated to demonstrate significant market growth owing large number of veterinarian clinics, investment in healthcare, and focus on animal health. According to the North American Meat Institute, the US exported 3.7 million metric tons (MT) of poultry and poultry variety meats in 2017. This is expected to accelerate the demand for avian influenza vaccines among the populace. Recently, a cell-based vaccine, Audenz, by Seqirus has been approved by the U.S. FDA for use among children 6 and older.

Competition Outlook

JOVAC, Avimex Animal Health, Guangdong Wenshi Dahuanong Biotechnology Co., Ltd, Medion, Zoetis, Tianjin Ringpu Bio-Technology Co., Ltd, QYH BIOTECH COMPANY LIMITED, Boehringer Ingelheim International GmbH, CAVAC, PT Japfa Comfeed Indonesia Tbk, Chengdu Tech-bank Biological Products Co., Ltd, Merck Animal Health, Ceva, FATRO S.P.A., and Yebio Bioengineering Co., Ltd, are key players of the global avian influenza vaccine market.